A CONTROLLED CLINICAL-TRIAL OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN TYPE-I DIABETIC NEPHROPATHY - STUDY DESIGN AND PATIENT CHARACTERISTICS

A CONTROLLED CLINICAL-TRIAL OF ANGIOTENSIN-CONVERTING ENZYME-INHIBITION IN TYPE-I DIABETIC NEPHROPATHY - STUDY DESIGN AND PATIENT CHARACTERISTICS

A placebo-controlled, double-blind clinical trial has been initiated to determine whether angiotensin-converting enzyme inhibitor (ACEI) therapy with captopril (25 mg three times daily) slows the progressive loss of renal function in patients with type 1 diabetes mellitus. Entry criteria include; (1...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Society of Nephrology 1992-10, Vol.3 (4), p.S97-S103
Hauptverfasser: BAIN, R, ROHDE, R, HUNSICKER, LG, MCGILL, J, KOBRIN, S, LEWIS, EJ
Format: Artikel
Sprache:eng
Schlagworte:
Life Sciences & Biomedicine
Science & Technology
Urology & Nephrology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A placebo-controlled, double-blind clinical trial has been initiated to determine whether angiotensin-converting enzyme inhibitor (ACEI) therapy with captopril (25 mg three times daily) slows the progressive loss of renal function in patients with type 1 diabetes mellitus. Entry criteria include; (1) ages 18 to 50 yr; (2) onset of insulin-dependent diabetes before the age of 30 yr, insulin dependent for at least 7 yr; (3) 24-h urine protein excretion >500 mg, plus: (a) diabetic retinopathy or (b) if no retinopathy, a renal biopsy diagnosis of diabetic nephropathy; (4) serum creatinine (SCr)
ISSN:1046-6673